CDMO Market Analysis 2026: Size, Trends & Key Players

The global CDMO industry has evolved from a cost-reduction outsourcing play into a critical strategic capability for the pharmaceutical and biotechnology industry. As drug development shifts toward increasingly complex modalities — antibody-drug conjugates, cell and gene therapies, bispecific antibodies, mRNA therapeutics — the manufacturing expertise required has outpaced what most biopharma companies can build internally. The result is a CDMO market worth about $197 billion in 2025 and about $211 billion in 2026 on Precedence Research’s estimates, growing at roughly 7% a year.

Simultaneously, the CDMO landscape is being reshaped by geopolitical forces that would have been unimaginable a decade ago. The BIOSECURE Act — signed into US law on December 18, 2025 — is accelerating the most significant geographic rebalancing of pharmaceutical manufacturing capacity since globalization opened China as a low-cost manufacturing hub in the 2000s. Many companies that relied on WuXi AppTec, WuXi Biologics, and other Chinese CDMOs are adding alternative capacity in the US, Europe, South Korea, Japan, and India, even as the leading Chinese CDMOs report record order books.

This analysis provides a detailed examination of the CDMO market: its size and growth trajectory, the competitive landscape of key players, segment-level dynamics across biologics, small molecule, and cell & gene therapy manufacturing, the geographic rebalancing driven by regulatory and geopolitical forces, and a practical framework for selecting a CDMO partner. For a deeper analysis of the BIOSECURE Act’s regulatory mechanics, see our dedicated article on the BIOSECURE Act’s impact on pharma.

Market Size & Growth Trajectory

Published estimates of the CDMO market vary with how each firm defines it, from $136.6 billion (BCC Research, 2024) to about $197 billion (Precedence Research, 2025). They agree on steady growth of around 7% a year. Three structural forces drive it: more outsourcing by drug developers of every size, the rising complexity of novel modalities that require specialized manufacturing expertise, and a growing biologics pipeline.

Source	Recent Size	Forecast	Annual Growth
Precedence Research	$197.4B (2025); $211B (2026)	$368.7B (2034)	7.2%
Grand View Research	~$166B (2025)	~$235.5B (2030)	7.4%
BCC Research	$136.6B (2024)	$191.6B (2029)	7.0%
Cell & gene therapy CDMO (Precedence Research)	$8.1B (2025)	~$74B (2034)	—

Each firm defines the market differently, so the figures are not directly comparable. Grand View Research figures as summarized by PharmaSource.

Growth is fastest in biologics — monoclonal antibodies, ADC and bispecific antibody programs — and in cell and gene therapy manufacturing. Small molecule work grows more slowly but remains a large, stable base built on complex APIs, high-potency compounds, and controlled substances. The leaders’ results show the pace: Lonza’s 2025 sales rose 21.7% at constant exchange rates, Samsung Biologics’ revenue 30.3%, and WuXi Biologics’ 16.7%.

Key Growth Drivers

Biologics Pipeline Expansion

Thousands of biologics are in clinical development globally. Each program needs process development, cell line development, clinical manufacturing, and eventually commercial supply. This translates to sustained demand for CDMO services across the development lifecycle.

Manufacturing Complexity

Novel modalities (ADCs, bispecific antibodies, cell therapies, mRNA) require specialized equipment, clean rooms, and process expertise that most biotechs cannot build internally. Even large pharma companies outsource a meaningful share of novel modality manufacturing.

Capital Efficiency Pressure

A large cGMP plant can cost billions and take years to build: FUJIFILM’s Holly Springs, North Carolina site cost $3.2 billion and opened in September 2025, more than four years after it was announced. For clinical-stage biotechs, outsourcing to a CDMO is the only viable path. Even for commercial-stage companies, the capital efficiency of outsourcing vs. owning capacity favors CDMOs for all but the highest-volume products.

Regulatory & Geopolitical Shifts

The BIOSECURE Act and broader supply chain resilience concerns are driving companies to diversify manufacturing across multiple geographies. This "dual-sourcing" trend adds CDMO demand from companies that previously relied on a single supplier.

Key Players: The CDMO Competitive Landscape

The CDMO market is fragmented, with hundreds of providers ranging from global groups to single-site specialists, and it is consolidating through M&A. Novo Holdings bought Catalent for about $16.5 billion in December 2024, while Novo Nordisk bought three Catalent fill-finish sites for $11 billion; Lonza bought Genentech’s large-scale biologics site in Vacaville, California for $1.2 billion in October 2024. The strategic dynamics differ significantly across the biologics, small molecule, and cell & gene therapy segments.

Biologics CDMOs

Company	HQ	Revenue (2025)	Key Capabilities	BIOSECURE Status
Lonza	Switzerland	CHF 6.5B (~$8B)	mAbs, ADCs, cell & gene therapy, mRNA	Not designated
Samsung Biologics	South Korea	KRW 4.56T (~$3.2B)	mAbs, bispecifics, large-scale (784,000L capacity)	Not designated
WuXi Biologics	China	RMB 21.8B (~$3.0B)	mAbs, bispecifics, ADCs	Not designated; named in the 2024 House bill
Catalent (Novo Holdings)	US	Private	Biologics, gene therapy, oral delivery, analytical	Not designated
FUJIFILM Biotechnologies	Japan	—	mAbs, gene therapy, vaccines, large-scale cell culture	Not designated
Boehringer Ingelheim	Germany	—	mAbs, cell therapy, microbial expression	Not designated
AGC Biologics	Japan	—	mAbs, plasmid DNA, cell therapy	Not designated

Revenue as reported for 2025, with approximate US dollar conversions; a dash means no comparable figure is shown. Status as of October 2026: no company named in the enacted BIOSECURE Act, and the first OMB list is due by December 18, 2026.

Small Molecule CDMOs

Small molecule work remains a large, stable part of the CDMO market, anchored by complex APIs and intermediates, high-potency compounds, and controlled-substance production. Key players include:

Company	HQ	Revenue	Key Strengths
WuXi AppTec (WuXi STA)	China	RMB 19.9B (~$2.8B, 2025)	Full CRO+CDMO integration, cost-competitive, vast chemistry capacity
Thermo Fisher (Patheon)	US	—	End-to-end services, sterile fill-finish, complex formulations
Siegfried	Switzerland	CHF 1.33B (~$1.6B, 2025)	Complex APIs, controlled substances, high-potency
Recipharm	Sweden	€827M (~$0.9B, 2024)	Oral solid dose, inhalation, complex APIs
Piramal Pharma Solutions	India	—	Cost-competitive, complex APIs, peptide manufacturing
Curia (formerly AMRI)	US	Private	Small molecule API, drug product, analytical services

WuXi AppTec figure: its small-molecule development and manufacturing business; the wider WuXi Chemistry segment made RMB 36.5 billion in 2025. A dash means no comparable figure is shown.

Cell & Gene Therapy CDMOs

Cell and gene therapy manufacturing is the fastest-growing CDMO segment and arguably the most strategically important. The manufacturing complexity of viral vectors (AAV, lentiviral), CAR-T cells, and in vivo gene therapies creates high barriers to entry. After a wave of capacity building, the segment is also consolidating: Thermo Fisher is consolidating its viral vector sites, and National Resilience decided in June 2025 to wind down six of its ten sites.

Key players in this segment include:

Lonza: One of the largest cell and gene therapy manufacturers, with dedicated facilities including its site in Houston, Texas.
Catalent (Novo Holdings): Strong position in gene therapy viral vector manufacturing. Privately held since December 2024, with Novo Holdings’ backing for continued investment.
FUJIFILM Biotechnologies: Offers gene therapy services alongside its large-scale antibody plants. Its new $3.2 billion Holly Springs, North Carolina site, opened in September 2025, is a cell culture plant for antibodies.
Oxford Biomedica: UK-based viral vector specialist, best known for lentiviral vectors, which helped manufacture more than 100 million doses of the Oxford–AstraZeneca COVID-19 vaccine during the pandemic.
Thermo Fisher (Brammer Bio): Bought Brammer Bio for $1.7 billion in 2019. It is now consolidating viral vector work in Plainville, Massachusetts, and closing its Lexington, Massachusetts site and its Alachua, Florida plant.

Estimates of the cell & gene therapy CDMO market for 2025 range from about $3.8 billion (Global Market Insights) to about $8.1 billion (Precedence Research), and Precedence projects about $74 billion by 2034. Growth is driven by the expansion of approved cell therapies (CAR-T, TCR-T), the emergence of in vivo gene editing programs, and the growing number of clinical-stage programs requiring GMP viral vector supply.

Geographic Trends: The Great Rebalancing

The CDMO market is undergoing a historic geographic rebalancing driven by three converging forces: the BIOSECURE Act, broader supply chain resilience concerns (accelerated by COVID-19 disruptions), and geopolitical tensions between the US/EU and China. Asia Pacific already holds the largest share of the market, about 42% in 2024 (Precedence Research), so the rebalancing is as much about which Asian providers win as about reshoring.

China: From Growth Engine to Strategic Risk

China’s CDMO industry grew rapidly over the past fifteen years on lower costs, a large chemistry workforce, and aggressive capacity investment by WuXi AppTec, WuXi Biologics, Asymchem, and others. It is still growing: WuXi Biologics reported record 2025 revenue of RMB 21.8 billion, a record 209 new integrated projects, and a $23.7 billion backlog, while WuXi AppTec’s chemistry business grew 25.5%.

The BIOSECURE Act changes the risk calculus for Western sponsors. Key dynamics:

Client migration: Companies with US government exposure (federal contracts, grants, or loans) need a plan for any work done by a designated company. The prohibitions are expected to apply from around late 2028, with up to five years of grandfathering for existing contracts — except for companies already on the 1260H list when the law passed, such as BGI. Technology transfer can take a year or more for biologics, so planning needs to start well ahead.
Pricing impact: Companies not directly affected by the law are weighing Chinese CDMOs’ cost advantages against the cost and delay of a possible future switch, which makes the CDMO choice a deal and valuation question, not only a procurement one.
Capacity implications: WuXi AppTec was added to the Pentagon’s 1260H list in June 2026, but a federal court preliminarily blocked the designation in August 2026; WuXi Biologics has not been designated. WuXi AppTec had already sold the US and UK operations of its cell and gene therapy unit, WuXi Advanced Therapies, to Altaris in early 2025. For a broader perspective on the evolving China biopharma landscape and its deal-making implications, see our China biotech licensing opportunities guide.

South Korea, Japan & India: The Alternative Asia

Non-Chinese Asian CDMOs are well placed to win work from sponsors that want an alternative:

South Korea: Samsung Biologics is the clear leader, with 784,000L of bioreactor capacity since its fifth plant began operating in April 2025. It is investing KRW 7.5 trillion (about $5.6 billion) in Bio Campus II, Plants 5–8, and booked record orders of KRW 5.4 trillion in 2024 and more than KRW 5.5 trillion in 2025.
Japan: FUJIFILM Biotechnologies (formerly Fujifilm Diosynth) opened its $3.2 billion Holly Springs, North Carolina plant in September 2025, with eight 20,000L bioreactors, eight more planned, and Johnson & Johnson as anchor customer; it also runs large-scale sites in Denmark and the UK. AGC Biologics operates sites in Japan, the US, and Europe.
India: India’s CDMO industry is predominantly small molecule and generic API focused. Companies like Piramal, Syngene, and Aragen are positioning for complex molecule manufacturing, but biologics CDMO capabilities remain limited compared to Korea and Japan. India’s strength is cost-competitive chemistry and large-scale generic API production.

US & Europe: Reshoring & Capacity Expansion

The US and European CDMO markets are in a major capacity expansion cycle, though not every bet has paid off:

United States: The largest recent projects include FUJIFILM’s $3.2 billion Holly Springs plant and Lonza’s Vacaville, California site, bought from Genentech in 2024 for $1.2 billion with about 330,000L of bioreactor capacity. At the other end, National Resilience decided in June 2025 to wind down six of its ten sites and focus on Cincinnati and Toronto, after its CEO said capacity expansion had outpaced industry demand.
Europe: Lonza continues to invest in its Swiss facilities in Visp. Boehringer Ingelheim runs large-scale biopharmaceutical production in Vienna, and Siegfried and Recipharm compete in complex APIs and drug product. The EU’s Critical Medicines Alliance supports manufacturing resilience for essential medicines.

Region	Strengths	Leading CDMOs	BIOSECURE Impact
North America	Biologics, drug product, new large-scale capacity	Thermo Fisher (Patheon), Catalent, Lonza, FUJIFILM	Positive — gains from diversification
Europe	Biologics, complex APIs, cell & gene therapy	Lonza, Boehringer Ingelheim, Siegfried, Recipharm	Positive — gains from diversification
China	Integrated discovery-to-manufacturing, cost, speed	WuXi AppTec, WuXi Biologics, Asymchem	Negative — designation risk for US-facing work
South Korea	Largest single-company biologics capacity	Samsung Biologics	Positive — gains from diversification
Japan	Large-scale biologics, gene therapy	FUJIFILM Biotechnologies, AGC Biologics	Positive — gains from diversification
India	Small molecule, generic APIs, chemistry services	Piramal, Syngene, Aragen	Neutral — limited biologics exposure

How to Choose a CDMO Partner

CDMO selection is one of the most consequential supply chain decisions a biopharma company makes — and increasingly, firms are engaging strategic partnership advisors to navigate the process. A poor choice can result in months of manufacturing delays, batch failures that consume limited API supply, regulatory observations that delay approval, and — in the worst case — program termination due to inability to produce drug product to specification. Here is a systematic framework for CDMO evaluation.

Core Selection Criteria

Technical Capability & Modality Fit

Does the CDMO have demonstrated experience with your specific modality? A biologics CDMO is not a cell therapy CDMO. An ADC manufacturer needs conjugation chemistry and high-potency handling capabilities that most biologics CDMOs lack. Ask for specific process development case studies in your modality — not just general capabilities brochures.

Regulatory Track Record

How many successful FDA/EMA pre-approval inspections has the CDMO hosted? What was the outcome of the most recent regulatory inspection? CDMOs with clean inspection histories and experience supporting NDA/BLA filings in your target markets are significantly lower risk. Request the last 3 FDA inspection reports (483s) and the CDMO's corrective action responses.

Capacity & Scalability

Does the CDMO have available capacity for your clinical manufacturing needs today AND the ability to scale for commercial supply? Capacity for in-demand services can be tight and create long wait times. Understand the CDMO's current utilization, expansion plans, and commitment to reserving capacity for your program.

Geographic & Geopolitical Considerations

Where is the CDMO located relative to your target markets? Will manufacturing in this location create regulatory, supply chain, or BIOSECURE compliance concerns? Increasingly, companies are dual-sourcing across geographies (e.g., US + EU, or Korea + US) to mitigate geographic concentration risk.

Financial Stability & Investment

Is the CDMO financially stable enough to honor multi-year commitments? Companies backed by private equity may face cost-cutting pressure that affects quality. CDMOs with strong balance sheets or strategic owners (Samsung, Fujifilm, Novo Holdings/Catalent) provide greater assurance of sustained investment in people, facilities, and technology.

Intellectual Property Protection

How does the CDMO protect your process IP, formulation know-how, and proprietary data? What are the confidentiality provisions, and does the CDMO segregate client information physically and digitally? For companies working with Chinese CDMOs, IP protection mechanisms must be evaluated with additional rigor.

Stage-Specific CDMO Selection Considerations

Development Stage	Priority Criteria	Common Mistakes
Preclinical / IND-Enabling	Speed to GMP material, process development expertise, flexibility for process changes	Choosing on cost alone; selecting a large CDMO that deprioritizes small programs
Phase 1-2 Clinical	Analytical capabilities, process optimization, tech transfer readiness, regulatory filing support	Not planning for scale-up; locked into a CDMO that cannot support Phase 3 volumes
Phase 3 / Pre-Approval	Process validation capability, regulatory inspection readiness, supply reliability, commercial scale	Changing CDMOs at this stage (can add a year or more); underestimating PAI preparation
Commercial	Cost competitiveness, supply chain reliability, multi-year capacity commitment, quality consistency	Single-sourcing without backup; not negotiating cost reductions for volume commitments

If you are new to outsourcing, our guide to CRO vs CDMO explains what each type of provider does, how their contracts are priced and how to choose one.

Emerging Trends Reshaping the CDMO Industry

Beyond the BIOSECURE-driven geographic rebalancing, several technology and business model trends are reshaping the CDMO landscape.

Continuous Manufacturing

Traditional pharmaceutical manufacturing uses batch processes — discrete production runs with start-and-stop cycles. Continuous manufacturing runs production without interruption, offering advantages in efficiency, quality (real-time quality control), and environmental footprint (smaller facilities, less waste). The FDA has actively encouraged adoption and in March 2023 adopted the international ICH Q13 guideline on continuous manufacturing of drug substances and drug products, which covers biologics and biosimilars as well as small molecules.

Specialists such as Continuus Pharmaceuticals focus on continuous flow manufacturing, and larger CDMOs offer continuous processing for selected products. Adoption remains early-stage, and broader uptake depends on how quickly sponsors and regulators gain experience with the approach.

AI & Digital Manufacturing

Artificial intelligence is beginning to transform CDMO operations across multiple dimensions:

Process development: AI-powered design of experiments (DoE) can shorten process development by predicting optimal conditions from smaller datasets.
Predictive quality: Machine learning models that predict batch quality in real-time, enabling proactive intervention before out-of-spec conditions occur. This is particularly valuable for biologics, where a single failed batch is expensive.
Supply chain optimization: AI-driven demand forecasting and inventory management across multi-site CDMO networks, improving capacity utilization and reducing lead times.
Digital twins: Virtual replicas of manufacturing processes that enable in silico process optimization, scale-up prediction, and troubleshooting without consuming physical materials or production time.

Modular & Prefabricated Facilities

Traditional pharmaceutical manufacturing facilities take years to build and can cost billions. Modular construction — using prefabricated, self-contained manufacturing pods that can be assembled like building blocks — can shorten build times and reduce cost.

Companies leading modular facility adoption include G-CON Manufacturing (modular cleanroom pods) and Just–Evotec Biologics (J.POD continuous bioprocessing platform). This trend is particularly important for cell & gene therapy manufacturing, where smaller-scale, highly flexible facilities are more appropriate than traditional large-scale bioreactor farms.

Biosimilars & the Manufacturing Capacity Crunch

The biosimilar wave — driven by patent cliffs on major biologics including Humira, Keytruda (2028), Opdivo (2028), and Stelara (2025) — is creating additional demand for CDMO biologics manufacturing capacity. Biosimilar manufacturers (Biocon, Samsung Bioepis, Sandoz, Celltrion) need substantial clinical and commercial manufacturing capacity, competing with innovator biotechs for the same CDMO resources.

Companies that secure multi-year manufacturing agreements with capacity commitments are better positioned than those relying on spot capacity.

Strategic Implications for Biopharma Companies

The CDMO market dynamics described above have concrete strategic implications for pharmaceutical and biotechnology companies of all sizes:

Lock in capacity early. Capacity for in-demand services can be tight, so companies that secure CDMO relationships 12-18 months before they need manufacturing capacity will avoid the queue. This means initiating CDMO selection during preclinical development, not after IND approval.
Plan for dual-sourcing. Single-source manufacturing — whether at a Chinese CDMO or a Western one — creates unacceptable supply chain risk. Companies should plan for dual-sourcing from the outset, ideally across different geographies. The incremental cost of maintaining two qualified manufacturing sites is insurance against single-point-of-failure disruptions.
Factor CDMO into deal structuring. For companies evaluating licensing or partnership deals, the manufacturing strategy is a critical component of due diligence. Assets manufactured at a CDMO that is, or may be, designated under BIOSECURE may need a technology transfer — adding cost and timeline to the deal. This should be reflected in deal economics.
Consider CDMO partnerships as strategic assets. Long-term CDMO relationships with established quality histories and regulatory track records are strategic assets, not commodity contracts. Companies that invest in these relationships — through multi-year commitments, dedicated suites, and co-investment in capacity — achieve better outcomes than those that treat CDMOs as interchangeable vendors.
Monitor the BIOSECURE compliance timeline. Companies with any US government exposure (federal contracts, grants, or loans) should begin CDMO transition planning now. The first OMB list of biotechnology companies of concern is due by December 18, 2026, and the prohibitions are expected to apply from around late 2028; technology transfer for biologics can take a year or more, which leaves limited margin for delay.

Frequently Asked Questions

How large is the global CDMO market?

Estimates depend on how the market is defined. Precedence Research puts the pharmaceutical CDMO market at about $197 billion in 2025 and about $211 billion in 2026, growing roughly 7% a year to about $369 billion by 2034. BCC Research sizes it at $136.6 billion in 2024, rising to $191.6 billion by 2029, and Grand View Research at about $166 billion in 2025. Cell and gene therapy is the fastest-growing niche but still small: estimates for 2025 range from about $3.8 billion to about $8.1 billion.

Who are the largest CDMOs in the world?

Among CDMOs that publish comparable figures, the largest include Lonza (CHF 6.5 billion of 2025 sales, about $8 billion), Samsung Biologics (KRW 4.56 trillion, about $3.2 billion), WuXi Biologics (RMB 21.8 billion, about $3.0 billion) and WuXi AppTec, whose small-molecule development and manufacturing business made RMB 19.9 billion (about $2.8 billion) in 2025. Siegfried (CHF 1.33 billion in 2025) and Recipharm (€827 million in 2024) are leading mid-sized players. Thermo Fisher (Patheon), Catalent (privately held by Novo Holdings since December 2024), FUJIFILM Biotechnologies, Boehringer Ingelheim and AGC Biologics are also among the largest providers.

How will the BIOSECURE Act affect the CDMO market?

The BIOSECURE Act became law on December 18, 2025 as Section 851 of the FY2026 National Defense Authorization Act. Unlike the 2024 House bill, it names no companies. Biotechnology companies of concern are those on the Pentagon’s 1260H list with a biotechnology link, plus any that the Office of Management and Budget designates; its first list is due by December 18, 2026. Federal agencies will be barred from buying biotechnology equipment or services from these companies, and from contracting with or funding companies that use them in federally funded work. The prohibitions are expected to apply from around late 2028, with up to five years of grandfathering for existing contracts. WuXi AppTec was added to the 1260H list in June 2026, but a federal court preliminarily blocked that designation in August 2026, and WuXi Biologics has not been designated. Many sponsors are still adding non-Chinese capacity to reduce the risk.

How should a biotech company choose a CDMO partner?

Key selection criteria include: technical capabilities aligned with your modality (biologics, small molecule, CGT), regulatory track record (successful FDA/EMA inspections), capacity availability and scalability, geographic location (considering supply chain resilience and BIOSECURE compliance), financial stability (ability to invest in capacity and technology), cultural fit and communication quality, and intellectual property protections. For clinical-stage programs, speed to IND-enabling manufacturing is often the most critical factor. For commercial programs, reliability, scale, and cost competitiveness are paramount.

Conclusion: Manufacturing as Strategy

The CDMO market is no longer a back-office procurement topic — it is a board-level strategic issue. The convergence of manufacturing complexity (novel modalities), regulatory disruption (BIOSECURE), geopolitical rebalancing (supply chain resilience), and capacity constraints means that companies’ CDMO strategies directly affect their ability to advance programs, secure partnerships, and deliver medicines to patients.

For biopharma executives, the message is clear: invest in CDMO relationships early, plan for geographic diversification, and treat manufacturing strategy as an integral part of corporate development — not an afterthought delegated to procurement. Companies that get this right will have a genuine competitive advantage. Those that do not will face delays, cost overruns, and supply chain disruptions that erode program value and shareholder returns.

At Vision Lifesciences, with teams in Hong Kong, Shanghai, Zurich, and Chicago, we help biopharma companies navigate the CDMO landscape as part of our broader cross-border advisory services. Whether you are evaluating CDMO options as part of a licensing deal, conducting supply chain due diligence on an acquisition target, or restructuring your manufacturing strategy in response to BIOSECURE, our team brings deep industry knowledge and cross-border perspective to the decision.

Navigating CDMO Strategy Across Borders?

From BIOSECURE compliance planning to CDMO partner evaluation and cross-border manufacturing strategy, our team helps biopharma companies make informed decisions in a rapidly changing landscape.

Sources

Need expert guidance on your next deal?

Our team of life sciences advisors can help you navigate complex transactions, from early-stage licensing to full M&A.